MT 1013
Alternative Names: MT-1013Latest Information Update: 21 Aug 2025
At a glance
- Originator Shaanxi Micot Technology Co
- Class Peptides
- Mechanism of Action Calcium-sensing receptor agonists; Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Secondary hyperparathyroidism
- No development reported Calcium metabolism disorders; Phosphorus metabolism disorders
Most Recent Events
- 14 Aug 2025 Shaanxi Micot Pharmaceutical plans a phase III trial for Secondary hyperparathyroidism in China (IV) in September 2025(NCT07122401) .
- 28 Nov 2024 No recent reports of development identified for phase-I development in Calcium-metabolism-disorders(In volunteers) in USA (Parenteral, Injection)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Phosphorus metabolism disorders(In volunteers) in USA (Parenteral, Injection)